Novartis Pharmaceuticals Corporation recalls Xiidra (lifitegrast ophthalmic solution) 5% PROFESSIONAL SAMPLE, packaged in a) 5 single-use containers (0.2 mL each vi…
- Recall date
- May 10, 2022
- Source
- U.S. Food & Drug Administration (FDA) — enforcement report
- Recall number
- D-0985-2022
- FDA classification
- Class III
- Brand / firm
- Novartis Pharmaceuticals Corporation
- Sold / distributed
- Nationwide within the United States
Why it was recalled
Failed Impurities/Degradation Specifications.
Class III means the product violates regulations but is not likely to cause harm.
What was recalled
Xiidra (lifitegrast ophthalmic solution) 5% PROFESSIONAL SAMPLE, packaged in a) 5 single-use containers (0.2 mL each vial) (NDC 54092-606-07) and b) 4 pouches x 5 single-use containers (NDC 54092-606-04), Rx Only, Manufactured for: Shire US Inc., 300 Shire Way, Lexington, MA 02421.
Get recall alerts
Free email alert whenever Novartis Pharmaceuticals Corporation has a new recall — straight from official government data. Unsubscribe anytime.
More recalls from: Novartis Pharmaceuticals Corporation